Drug Trial Radar · NCT04683354
Study of HL-085 in Patients With Advanced Solid Tumor Tumors
Last checked: Nov 19, 2026Latest source record: Feb 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Dec 23, 2020
Primary completion
Sep 15, 2022
Study completion Dec 8, 2022
Sponsor
- Lead sponsor
- Kechow Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigational product (IP) HL-085 is an adenosine triphosphate-noncompetitive mitogen activated protein kinase (MEK) inhibitor with a strong selective anti-tumor activity, with a much lower dose than selumetinib. It has been shown strong anti-tumor activities in preclinical studies to treat solid tumors, e.g., melanoma, non-small cell lung cancer, colon cancer and other malignancies with RAF and RAS mutations. Kechow has completed phase I dose escalation study to test HL-085 in patients with advanced NRAS mutated melanoma in China. The tested doses were 0.5 mg, 1mg, 2mg, 3mg, 4mg, 6mg, 9mg, 12mg, 15mg and 18mg BID oral administration and there was no dose-limiting toxicity (DLT) identified. All patients tolerated the study drug reasonably well. This study is a Phase I, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetic (PK) and preliminary antitumor activities of HL-085 in US patients with advanced solid tumors. The objective of the dose escalation is to evaluate safety and tolerability of selected TID and BID dose regimens in US patient population with advanced solid tumor and establish the Recommended Phase 2 Dose (RP2D). The starting dose for this trial is 12 mg daily oral administration. Three selected daily doses - 12 mg (4mg TID, 6mg BID), 18 mg (6mg TID, 9 mg BID), and 24 mg (8 mg TID, 12 mg BID) will be tested in this study to assess safety and tolerability of HL-085 at the 3 selected dose levels in US patient population with advanced solid tumors.
Conditions
- Solid Tumor, Adult
Interventions
HL-085Drug
HL-085 is a MEK inhibitor with potential indication for cancers. It will be given twice or three times daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative antitumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterize the safety profile of the study drug at 3 dose levels in terms of number of treatment emergent events assessed by CTCAE v5.0., abnormal clinical laboratory and electrocardiograms findings (i.e. QT and QTc intervals).Time frame: 7 months (6 months treatment + 1 month follow-up)
- Cmax: the maximum plasma concentration of HL-085 or metabolite(s);Time frame: 1 month (Cycle 1 Day 1-31)
- Tmax: the time of Cmax;Time frame: 1 month (Cycle 1 Day 1-31)
- Area under the curve at steady state: a measure of the exposure to HL-085 or metabolite(s) at steady state.Time frame: 1 month (Cycle 1 Day 1-31)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
CCARE
San Marcos, California
Comprehensive Cancer Centers
Las Vegas, Nevada
Gabrail Cancer Center
Canton, Ohio
SCRI
Nashville, Tennessee
Oncology Consultants
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.